Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 11/08/24
ATTENTION AZN SHAREHOLDERS: Investors who lost money on AstraZeneca PLC are urged to contact Levi & Korsinsky about an ongoing investigationAccesswire • 11/07/24
Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 11/07/24
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024Business Wire • 11/07/24
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 EarningsZacks Investment Research • 11/06/24
AstraZeneca commits to cooperting with China fraud probe after billions wiped from valuationProactive Investors • 11/06/24
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investorsMarket Watch • 11/05/24
AstraZeneca sheds £15bn in value as weight loss drug data ‘underwhelming'Proactive Investors • 11/05/24
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerBusiness Wire • 10/30/24
AstraZeneca positioned for success in key breast cancer drug trials, says leading US investment bankProactive Investors • 10/25/24
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic DisorderBenzinga • 10/24/24
Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 DiabetesGlobeNewsWire • 10/23/24